About Minerva Biotechnologies
Minerva Biotechnologies is a private company based in Waltham, Massachusetts. It has reported $70,729,283 raised in eight offerings on Form D since February 2010. Its chief executive is Cynthia Bamdad.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2023 | Dec 5, 2023 | $4,515,000of $8.0M target | 9 | $501K | EquityRule 506(b) | Form D ↗ |
| Feb 14, 2022 | Feb 23, 2022amended Jan 4, 2023 | $327,720of $30.0M target | 5 | $65,544 | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 17, 2019 | Oct 30, 2019amended Jan 28, 2022 | $24,073,157of $30.0M target | 65 | $370K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 22, 2019 | Apr 5, 2019 | $4,231,000of $12.0M target | 9 | $470K | EquityRule 506(b) | Form D ↗ |
| Oct 10, 2014 | Oct 2, 2018 | $29,342,194of $31.2M target | 79 | $371K | EquityRule 506(b) | Form D ↗ |
| Oct 10, 2014 | Oct 24, 2014 | $2,000,000of $30.0M target | 1 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Nov 3, 2010 | Nov 17, 2010 | $4,634,580of $5.9M target | 17 | $272K | Equity, Options06 | Form D ↗ |
| Jul 7, 2009 | Feb 23, 2010 | $1,605,632of $5.0M target | 20 | $80,282 | Equity06 | Form D ↗ |
| Total, eight offerings | $70,729,283 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Minerva Biotechnologies's Form D filed Dec 5, 2023.
KK
Kenneth Kosik
Director
JB
James Bridges
Director
RS
Robert Staszewski
Director
RA
Ronald Axelrod
Director
JN
Joseph Nathan
Director
LC
Lawrence Coolidge
Director
KR
Kenneth Reed
Director
CB
Cynthia Bamdad
President & Chief Executive Officer, director
Earlier filings also listed Normand Smith (director, last listed Apr 2019).